EUROPEAN COLORECTAL CONGRESS

Spotlight on the colon

1 – 5 December 2019, St.Gallen, Switzerland

Sunday, 1 Dec. 2019

MASTERCLASS

09.00
When the appendix plays nasty: intraoperative surprises, immediate solutions, and long-term treatment options
Justin Davies, Cambridge, UK

09.40
All the secrets of the pelvic floor - common disorders and proven solutions
Julie Cornish, Cardiff, UK

10.20
taTME in 2020 – when the dust settles: current and innovative indications, implementation, and practical advices
Roel Hompes, Amsterdam, NL

11.30
Complete mesocolic excision: indications, surgical approaches, and pitfalls
Paris Tekkis, London, UK

12.10
The views of an Editor and the wisdom of an Expert: contemporary publications with the potential to change and improve practice
Neil Mortensen, Oxford, UK

14.00
To ostomize or not and when? The value and downside of a diverting stoma versus virtual ileostomy versus no stoma
Gabriela Möslein, Wuppertal, DE

14.40
Extended lymph node dissection: indications, surgical anatomy, and technical approaches
Peter Sagar, Leeds, UK

15.20
Is the longer the new better - how to safely extend the interval after neoadjuvant chemoradiotherapy prior to surgery for rectal cancer
Ronan O'Connell, Dublin, IE

16:30
The colorectal anastomosis: time-proven wisdom, innovative configurations, and salvage techniques
André d'Hoore, Leuven BE

17.10
All you need to know about stomas but never dared to ask
Willem Bemelman, Amsterdam, NL

17.50
The EBSQ Coloproctology Examination
Michel Adamina, Winterthur, CH

18.00
Wrap-up
Michel Adamina, Winterthur, CH

Monday, 2 Dec. 2019

SCIENTIFIC PROGRAMME

09.45
Opening and welcome
Jochen Lange, St.Gallen, CH

10.00
Pathophysiology and non-operative management of symptomatic uncomplicated diverticular disease
Robin Spiller, Nottingham, UK

10.30
Surgery of acute diverticulitis – evidence, eminence and real life
Willem Bemelman, Amsterdam, NL

11.00
Management of atypical diverticulitis
Dieter Hahnloser, Lausanne, CH

11.30
Hartmann reversal: open, laparoscopic or transanal?
Roel Hompes, Amsterdam, NL

13.30
The surgeon personality – influence on decision making, risk-taking and outcomes
Desmond Winter, Dublin, IE

14.00
SATELLITE SYMPOSIUM
Medtronic

15.00
Clinical applications of image-guided cancer surgery
Cornelis van de Velde, Leiden, NL

16.00
Volvulus of the colon – a treatment algorithm
Peter Sagar, Leeds, UK

16.30
Hereditary colorectal cancer syndromes: tailored surgical treatment
Gabriela Möslein, Wuppertal, DE

17.00
Lars Pahlman and Herand Abcarian (2015)
Herand Abcarian, Chicago, US

17.20
Lars Påhlman Lecture
Steven Wexner, Weston, US

Tuesday, 3 Dec. 2019

09.00
Robotic-assisted versus conventional laparoscopic surgery for rectal cancer
Amjad Parvaiz, Poole, UK

09.30
Robotic multivisceral resection
Paris Tekkis, London, UK

10.00
SATELLITE SYMPOSIUM
Karl Storz

11.30
Neoadjuvant chemotherapy for advanced colon cancer: clinical and pathological Results
Dion Morton, Birmingham, UK
Philip Quirke, Leeds, UK

12.30
Cytoreductive surgery and hyperthermic intraoperative chemotherapy for intestinal and ovarial cancers: lessons learned from 2 decades of clinical trials
Vic Verwaal, Aarhus, DK

14.30
Mechanical bowel obstruction: rush to the OR or stent and dine
Neil Mortensen, Oxford, UK

15.00
Controversies in IBD surgery
André d'Hoore, Leuven, BE

16.00
How to deal with IBD and dysplasia
Janindra Warusavitarne, London, UK

16.30
Perianal Crohn – avoiding delay and best surgical practice
Justin Davies, Cambridge, UK

17.00
Perianal Crohn – stem cells therapy and current medical approach
Gerhard Rogler, Zürich, CH

Wednesday, 4 Dec. 2019

09.00
Is anastomotic leak an infectious disease
Ronan O'Connell, Dublin, IE

09.30
Is it time to invest in robotic surgery?
Antonino Spinelli, Milan, IT

10.00
SATELLITE SYMPOSIUM
Intuitive

11.00
New developments in robotic systems
Alberto Arezzo, Torino, IT

12.00
Posterior component separation for abdominal wall reconstruction: evolution from open to minimal invasive using the robotic platform
Filip Muysoms, Gent, BE

14.00
Coloproctology 4.0 – the networked surgeon
Richard Brady, Newcastle upon Tyne, UK

14.30
SATELLITE SYMPOSIUM
Olympus

15.30
The elderly colorectal patient – functional outcomes and patient reported outcomes
Isacco Montroni, Faenza, IT

16.30
The microbiome and colorectal cancer
Philip Quirke, Leeds, UK

17.00
Surgical management of rectal endometriosis
Eric Rullier, Bordeaux, FR

17.30
EAES Presidential Lecture 3D printing for the general surgeon
Andrea Pietrabissa, Pavia, IT

Thursday, 5 Dec. 2019

09.00
Management of locoregionally advanced colon cancer
Torbjörn Holm, Stockholm, SE

09.30
ROUNDTABLE
Herand Abcarian, Chicago, US
Bill Heald, Basingstoke, UK

10.30
Artificial intelligence in colorectal surgery
Michele Diana, Strasbourg, FR

11.30
The mesentery in colonic diseases
Calvin Coffey, Luimneach, IE

12.00
Technical pearls and typical mistakes in minimal invasive colectomy
Antonio Lacy, Barcelona, ES

12.30
Choosing the right anastomotic technique in colon surgery
Roberto Persiani, Rom, IT

13.00
Precision surgery: past, present and future
Brendan Moran, Basingstoke, UK

13.30
Poster award
Michel Adamina, Winterthur, CH

Information & Registration

www.colorectalsurgery.eu

Systematic review

Meta-analysis of *KRAS* mutations and survival after resection of colorectal liver metastases

K. W. Brudvik[1], S. E. Kopetz[2], L. Li[3], C. Conrad[1], T. A. Aloia[1] and J.-N. Vauthey[1]

Departments of [1]Surgical Oncology, [2]Gastrointestinal Medical Oncology and [3]Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Correspondence to: Dr J.-N. Vauthey, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, Texas 77030, USA (e-mail: jvauthey@mdanderson.org)

Background: **In patients with advanced colorectal cancer, *KRAS* mutation status predicts response to treatment with monoclonal antibody targeting the epithelial growth factor receptor (EGFR). Recent reports have provided evidence that *KRAS* mutation status has prognostic value in patients with resectable colorectal liver metastases (CLM) irrespective of treatment with chemotherapy or anti-EGFR therapy. A meta-analysis was undertaken to clarify the impact of *KRAS* mutation on outcomes in patients with resectable CLM.**

Methods: **PubMed, Embase and Cochrane Library databases were searched systematically to identify full-text articles reporting *KRAS*-stratified overall (OS) or recurrence-free (RFS) survival after resection of CLM. Hazard ratios (HRs) and 95 per cent c.i. from multivariable analyses were pooled in meta-analyses, and a random-effects model was used to calculate weight and overall results.**

Results: **The search returned 355 articles, of which 14, including 1809 patients, met the inclusion criteria. Eight studies reported OS after resection of CLM in 1181 patients. The mutation rate was 27·6 per cent, and *KRAS* mutation was negatively associated with OS (HR 2·24, 95 per cent c.i. 1·76 to 2·85). Seven studies reported RFS after resection of CLM in 906 patients. The mutation rate was 28·0 per cent, and *KRAS* mutation was negatively associated with RFS (HR 1·89, 1·54 to 2·32).**

Conclusion: ***KRAS* mutation status is a prognostic factor in patients undergoing resection of colorectal liver metastases and should be considered in the evaluation of patients having liver resection.**

Paper accepted 12 May 2015

Published online 21 July 2015 in Wiley Online Library (www.bjs.co.uk). **DOI:** 10.1002/bjs.9870

Introduction

In the evaluation of patients for resection of colorectal liver metastases (CLM), extent of disease is the primary consideration. Resection of all viable disease with acceptable postoperative morbidity is crucial to maximize the survival benefit and achieve cure. Improvements in surgical and non-surgical techniques have increased the proportion of patients eligible for curative resection of CLM[1]. However, for a number of patients rapid recurrence or postoperative complications offset the benefit associated with surgery.

In the 1990s, several groups[2–4] published scoring systems to predict recurrence after resection of CLM on the basis of clinical parameters such as sex, age, tumour location, size and number, disease-free interval and disease stage. However, risk factors determined before the era of modern chemotherapy have been shown[5–7] to perform less well in recent series of patients with CLM, in whom liver resection was performed in combination with modern chemotherapy. Compared with clinical parameters that serve as surrogate markers for tumour biology, direct indicators of tumour biology may explain the diverse outcomes after resection of CLM and provide useful information to guide treatment of patients with CLM.

Currently, medical oncologists are using the mutation status of the Kirsten rat sarcoma viral oncogene homologue (*KRAS*) gene to select patients with advanced-stage colorectal cancer with wild-type *KRAS* for treatment with monoclonal antibodies that target the epithelial growth factor receptor (EGFR); the antibodies used are panitumumab and cetuximab[8–11]. Recently, mutations in the *KRAS* gene have received much attention as the most promising mutations for prognostication in patients undergoing resection of CLM[12–14], indicating that knowledge of *KRAS* mutation status may also be valuable for evaluation of patients for possible resection of CLM. To clarify

the value of *KRAS* mutation status in predicting outcome after resection of CLM, a systematic literature review and meta-analysis was performed of studies reporting overall (OS) and recurrence-free (RFS) survival stratified by *KRAS* mutation status (irrespective of chemotherapy and anti-EGFR treatment) in patients undergoing CLM resection.

Methods

Data sources and search strategy

A systematic literature review was performed in April 2014 using the US National Library of Medicine PubMed database, Embase and the Cochrane Library. A detailed search string was constructed to return full-text articles that reported studies with patients who had resection of CLM and that provided information regarding outcome and *KRAS* mutation status: 'colorectal AND cancer AND (liver OR hepatic) AND (metastasis OR metastases) AND (resection OR surgery OR hepatectomy) AND (mutation OR mutations) AND (*KRAS* OR *K*-RAS OR *NRAS* OR *N*-RAS OR *RAS*)'. The review adhered to the guidelines outlined in the PRISMA statement[15].

Selection criteria

To be included in the review, an article had to: report on a study that included and reported patients who underwent resection of CLM; include results of genetic testing for *KRAS* mutations; and include outcomes for survival or recurrence assessed against the mutations. Publication date was not an inclusion or exclusion criterion. Duplicate articles were removed and the title of the remaining articles was reviewed; if the title did not reveal a reason for exclusion, the abstract was used to determine whether the article or study met any of the following exclusion criteria: language other than English; primary cancer other than colorectal cancer; article type other than report of original research (review, editorial, letter, comment, case report, or abstract); only the primary tumour treated with surgery; oncological but not surgical outcome reported; survival or recurrence not a primary or secondary outcome; basic science report; or study in cell lines or animals. The reference lists of the remaining articles were assessed for missed studies meeting the inclusion criteria. A qualitative systematic literature review and critical evaluation of the evidence were performed. Articles reporting *KRAS* mutation effect estimates from multivariable analyses for OS and articles reporting RFS after resection of CLM were pooled in separate meta-analyses.



Fig. 1 PRISMA flow chart showing the article selection process. The search string was built to identify studies of patients undergoing resection of colorectal liver metastases (CLM) in whom survival was assessed according to *KRAS* mutation status. CRC, colorectal cancer; OS, overall survival; RFS, recurrence-free survival

Data extraction and outcome measures

The following data were extracted from the included articles: first author, study origin, year of publication, study period, sample size, metastatic site, rate of *KRAS* mutations, *KRAS* codons included in the mutational analysis, use of preoperative chemotherapy (regimen and number of patients), use of adjuvant chemotherapy (regimen and number of patients), summary of findings regarding survival, and multivariable effect estimates for OS and RFS (hazard ratio (HR), 95 per cent c.i., *P* value). The individual studies were graded into low or high risk of bias based on the Grading of Recommendations, Assessment Development and Evaluation (GRADE) Working Group criteria: quality of evidence, uncertainty about the balance between desirable and undesirable effects, uncertainty of

Table 1 Characteristics of the included studies

Reference	Year	Study origin	Study interval	*n**	Metastatic site
Kastrinakis *et al.*[26]	1995	Boston, USA	1982–1992	19	Liver
Russo *et al.*[17]	1998	Palermo, Italy	1988–1992	35†	Liver
Petrowsky *et al.*[19]	2001	Frankfurt, Germany	1985–1995	41	Liver
Cejas *et al.*[18]	2009	Madrid, Spain	1997–2007	110	Liver and lung
Nash *et al.*[16]	2010	New York, USA	1991–1997	188‡	Liver
Teng *et al.*[22]	2012	Taipei, Taiwan	2000–2010	292§	Liver
Stremitzer *et al.*[13]	2012	Vienna, Austria	2005–2010	60	Liver
Huang *et al.*[20]	2013	Taipei, Taiwan	2000–2010	228§	Liver
Umeda *et al.*[23]	2013	Okayama, Japan	1997–2009	100	Liver
Isella *et al.*[21]	2013	Torino, Italy	2008–2010	64	Liver
Vauthey *et al.*[14]	2013	Houston, USA	1997–2011	193	Liver
Karagkounis *et al.*[12]	2013	Baltimore, USA	2003–2008	202	Liver
Shoji *et al.*[25]	2014	Tokyo, Japan	2004–2009	108	Liver
Kemeny *et al.*[24]	2014	New York, USA	2003–2013	169	Liver

*Number of patients included with known *KRAS* mutation status. †Thirteen of 35 and ‡126 of 188 patients underwent resection. §These two publications were based on the same patient cohort.

variability in values and preference, and uncertainty about whether the intervention represents a wise use of resources (www.gradeworkinggroup.org). The following study characteristics were assessed in light of the GRADE criteria and a concern regarding individual study bias: sample size, heterogeneity of selection to chemotherapy and resection, unresectability, study interval, lung and not liver resections, *KRAS* codons tested, other included genes, heterogeneity regarding variables included in multivariable analysis, and consistency of findings.

Statistical analysis

The primary outcome of the study was OS after resection of CLM; the secondary outcome was RFS after resection of CLM. Meta-analyses were performed using HRs with 95 per cent c.i.; the chosen effect measure was dichotomous data, which were available in 11 articles (8 of which reported OS and 7 RFS). The effect measures were converted into logarithmic values and a random-effects model with inverse-variance method was used to calculate weight and overall results of the meta-analyses. Interstudy statistical heterogeneity was assessed with I^2 statistics, and moderate to high degree was assumed when the value was more than 30 per cent. Data were presented in Forest plots in which a HR of less than 1 represents better outcome and a HR of more than 1 represents worse outcome in patients harbouring a *KRAS* mutation. Funnel plot analyses were performed to evaluate the presence of publication bias. Where some summary statistics for OS were reported for patients with *KRAS* and wild-type mutations, but the HR and 95 per cent c.i. were not made available in the article, these studies were assessed individually and not included in the main meta-analysis. Stata/SE™ version 11·0 (StataCorp LP, College Station, Texas, USA) was used for the meta-analyses.

Results

Literature search result

The initial search returned 355 records (*Fig. 1*); after exclusions, 223 articles remained for assessment of eligibility. After application of the other exclusion criteria and review of reference lists for missed articles, 14 unique articles remained[12–14,16–26] (*Tables 1* and *2*). These 14 articles reported on 1809 patients, 1725 of whom had resection of CLM. The *KRAS* mutation rate among all patients was 30·6 per cent.

Assessment of the study characteristics based on the GRADE criteria found that two studies[16,17] ($n = 84$) included patients with unresectable CLM, one study[18] ($n = 17$) included patients with lung metastasis, one study[19] tested *KRAS* codons 12 only, and one study[20] ($n = 6$) included *BRAF* mutations in the survival analysis. The risk of individual study bias was assessed as low[12–14,16,18,20–25] and high[17,19,26] in the included articles.

KRAS mutation and overall survival

Eight[12–14,16,19,20,23,24] of the 14 studies reported OS after resection of CLM stratified by *KRAS* mutation status and were pooled in a meta-analysis (*Fig. 2*). Three[17,18,26] of the 14 studies did not perform multivariable analyses for OS, two[21,25] reported RFS only, and one[22] reported results from the same patient cohort as another study[20] that was included in the meta-analysis. The study by

Table 2 *KRAS* mutations, use of chemotherapy and survival findings in the included studies

Reference	*KRAS* mutation rate (%)	Codons	Chemotherapy for CLM			Findings regarding survival
			Preop. therapy	Adjuvant therapy	Regimen	
Kastrinakis *et al.*[26]	37	12, 13	0	0		*KRAS* mutation rate similar in long- and short-term survivors
Russo *et al.*[17]	43	12, 13	0	0	5-FU*	*KRAS* codon 13 mutation negatively associated with OS (but not codon 12 and not both)
Petrowsky *et al.*[19]	15	12	n.a.	n.a.	5-FU†	*KRAS* mutation not associated with OS
Cejas *et al.*[18]	32·0#	12, 13	0	110	5-FU ± OXA/IRI	*KRAS* mutation negatively associated with RFS, not OS
Nash *et al.*[16]	27·0	12, 13	16	n.a.	5-FU‡	*KRAS* mutation negatively associated with OS
Teng *et al.*[22]	38·0	12, 13	44	145	n.a.	*KRAS* mutation not associated with OS
Stremitzer *et al.*[13]	25	12, 13, 61	60	60	5-FU + OXA + BEV	*KRAS* mutation negatively associated with OS and RFS
Huang *et al.*[20]	36·7	12, 13, 14	52	193	n.a.	*KRAS*/*BRAF* mutations negatively associated with OS
Umeda *et al.*[23]	27·0	12, 13	33	85	5-FU ± OXA/IRI ± BEV**	*KRAS* mutation negatively associated with OS
Isella *et al.*[21]	33	12, 13, 61, 146	36	43	5-FU + OXA/IRI ± BEV††	*KRAS* mutation negatively associated with RFS (not in multivariable analysis)
Vauthey *et al.*[14]	17·6‡‡	12, 13, 61, 146	193	193	5-FU + OXA/IRI + BEV	*RAS* mutation negatively associated with OS, RFS (any site) and lung RFS, but not liver RFS
Karagkounis *et al.*[12]	29·0	12, 13	162	130	n.a.	*KRAS* mutation negatively associated with OS and RFS
Shoji *et al.*[25]	36·1	12, 13	n.a.	n.a.	n.a.§	*KRAS* mutation negatively associated with RFS
Kemeny *et al.*[24]	30·2	12, 13	n.a.	169	5-FU ± OXA/IRI + HAI¶	*KRAS* mutation negatively associated with RFS, not OS, in multivariable analysis

*Chemotherapy used in study, but only in patients with unresectable disease. Chemotherapy used at some point in †29, ‡161, §14 and ¶142 patients, but adjuvant for primary *versus* preoperative/adjuvant for liver frequencies not available (n.a.). #Liver *KRAS* mutation rate. **One patient received cetuximab before resection of colorectal liver metastases (CLM), and three patients received cetuximab/panitumumab after resection of CLM. ††Chemotherapy was given only to patients with initially unresectable CLM. ‡‡Includes *NRAS* mutations. 5-FU, 5-fluorouracil-based chemotherapy; OS, overall survival; OXA, oxaliplatin; IRI, irinotecan; RFS, recurrence-free survival; BEV, bevacizumab; HAI, hepatic arterial infusion.

Huang and colleagues[20] was included in the meta-analysis because these authors included *KRAS* mutations in the multivariable analysis. The eight studies included in the meta-analysis represented 1181 patients who underwent resection of CLM; in these patients the *KRAS* mutation rate was 27·6 per cent. The results from these eight studies were generally consistent and *KRAS* mutation was negatively associated with OS (HR 2·24, 95 per cent c.i. 1·76 to 2·85). The funnel plot did not suggest notable publication bias (data not shown).

Three early studies reported overall survival in 19[26], 13[17] and 110[18] patients who underwent resection of CLM without providing HR and 95 per cent c.i. for *KRAS* mutations from multivariable analysis. These studies were assessed individually; no significant association between *KRAS* mutation and OS was found.

KRAS mutation and recurrence-free survival

Seven[12–14,18,21,24,25] of the 14 studies included in the systematic literature review reported RFS. Multivariable Cox regression analysis was performed for all seven studies, and the HR data were pooled in a separate meta-analysis (*Fig. 3*). The seven studies reported a total of 906 patients undergoing resection of CLM; in these patients the *KRAS*



Fig. 2 Forest plot of association between *KRAS* mutation status and overall survival (OS) after resection of colorectal liver metastases in eight studies. *Only 126 of the 188 included patients underwent resection. A random-effects model with inverse-variance method was used for meta-analysis. Hazard ratios are shown with 95 per cent c.i.



Fig. 3 Forest plot of association between *KRAS* mutation status and recurrence-free survival (RFS) after resection of colorectal liver metastases in seven studies. A random-effects model with inverse-variance method was used for meta-analysis. Hazard ratios are shown with 95 per cent c.i.

mutation rate was 28·0 per cent. The results from these seven studies were consistent and *KRAS* mutation was negatively associated with RFS (HR 1·89, 95 per cent c.i. 1·54 to 2·32).

Discussion

In the meta-analyses reported here, *KRAS* mutations predicted inferior OS and inferior RFS among patients who had resection of CLM. The effect of *KRAS* mutations on survival cannot be attributed to the perioperative use of targeted agents, as perioperative anti-EGFR treatment was used in only four of 100 patients in just one study[23]. Furthermore, the superior RFS in patients with wild-type *KRAS* indicates that the impact of *KRAS* mutation in the present study was not due to treatment of recurrence with anti-EGFR.

KRAS mutations have been associated with migration and invasion through disruption of the actin cytoskeleton and regulation of integrin expression, among other mechanisms[27–29]. These behaviors are mediated via a wider class of effectors beyond the mitogen-activated protein kinase pathway, including Rho guanosine-5′-triphosphatases and Rap1[30,31]. As a result, the prognostic importance of activating *KRAS* mutations extends beyond their ability to predict sensitivity to anti-EGFR monoclonal antibodies, and *KRAS* mutations may reflect a more migratory and invasive tumour biology resulting in a propensity for early and frequent recurrences after resection of metastatic disease.

The pooled *KRAS* mutation rate in the present study, 30·6 per cent, was lower than the 35–45 per cent rates that have been reported in most studies of patients with metastatic colorectal cancer[13,14,19,32–34]. The high concordance of *KRAS* mutation status between primary colorectal tumours and metastatic sites (more than 90 per cent) indicates that mutations are acquired early in tumorigenesis, before metastatic spread[35,36]. As such, the lower rate of *KRAS* mutations in the present study is unlikely to be due to differences in the tissue source for the *KRAS* testing[18,37–39]. Instead, patients who are deemed candidates for surgery are more likely than those not deemed candidates for surgery to have oligometastatic disease, reflecting potential differences in metastatic propensity. The lower *KRAS* mutation rate in the present study is in agreement with recent findings demonstrating significantly higher *KRAS* mutation rates in patients with extrahepatic metastasis from colorectal cancer than in patients with CLM, and unresectable extrahepatic disease is in most patients considered a contraindication for resection of CLM[18,37,40].

Although the survival impact of *KRAS* mutations has been demonstrated across multiple studies utilizing the most common codons in *KRAS* (12 and 13)[32], recent data on resistance to anti-EGFR monoclonal antibodies have suggested that the current standard-of-care panel should be expanded to include codons in exons 3 (codon 61) and exon 4 (codon 146) of *KRAS*[41]. These *KRAS* alleles were included in several studies[13,14,21] in the present meta-analysis. The rarity of mutations in these additional alleles precludes testing of their individual prognostic impact, but their mutual exclusivity in patients[37] and ability to transform cells *in vitro* suggest that their oncogenic function is preserved and that these alleles should therefore be included in testing panels for assessment of *RAS* mutation status[9,42,43]. A recent analysis[9] indicated that *NRAS* mutations should also be considered in the determination of *RAS* mutation status. In one study[14] included in the present meta-analyses, the investigators analysed all *RAS* mutations (*NRAS* and extended *KRAS* to include codon 61 and 146); the addition of *NRAS* increased the yield of *RAS* mutations by 20 per cent and likely strengthened the impact of mutations on prognosis.

The main challenge in patients with CLM is to identify those who can derive a survival benefit from resection. Historically, predictors of survival were based on morphological characteristics of the primary tumour and metastases (including primary tumour location and TNM stage; number and size of liver metastases), carcinoembryonic antigen level, and the disease-free interval between detection of the primary tumour and metastasis. Various scores with combinations of these factors have been proposed to predict prognosis after resection of CLM[2–4,44–48]. However, in recent years, large single-institution studies have questioned the validity and clinical usefulness of risk scores[5–7]. Zakaria and colleagues[7] found that risk scoring systems had limited clinical value, and Kattan and co-workers[49] created a nomogram with better discriminatory ability to improve scoring in resectable CLM. The studies used in the present meta-analyses assessed many of these factors in multivariable analysis, and *KRAS* mutations consistently indicated an independent twofold increase in the risk of death (8 studies) or recurrence (7 studies). In recent years, investigators have proposed pathological and radiological responses to chemotherapy as alternative outcome endpoints for predicting survival after resection of CLM[50–52]. However, pathological response can be assessed only after surgery, and the survival association with radiological response was found to be present mostly in patients receiving preoperative antivascular endothelial growth factor therapy[50–53]. In this context, *KRAS* mutation stands out as a new predictor of prognosis in patients with resectable CLM. It has many advantages over tumour characteristics and response to chemotherapy, as *KRAS* mutation is an early event in carcinogenesis that appears to be unaffected by chemotherapy[54].

This study has several limitations. First, there may be heterogeneity between the studies regarding the definition of resectability (between centres and surgeons), the use of chemotherapy, and the factors analysed in multivariable analysis. Despite this, the effect of *KRAS* on survival was consistent in almost all of the included studies, and no studies were identified reporting a favourable outcome in patients harbouring *KRAS* mutations. Such findings would have been published by now, and the funnel plot analyses of the included studies did not suggest publication bias. Second, some patients with wild-type *KRAS* may have received anti-EGFR treatment at the time of recurrence after liver resection, which could explain the OS benefit in these patients. However, this concern would have applied only to OS and not to RFS, and the majority of the study intervals predated the approval of anti-EGFR treatment for colorectal cancer. Third, a recent editorial[55] raised the possibility that *KRAS* mutation may be a 'byproduct of patient selection' that would explain the association with inferior survival. However, up to now, surgeons have determined patient resectability based on tumour and biological characteristics irrespective of *KRAS* mutation status. Furthermore, *KRAS* mutation testing may have been utilized in the patients with the most extensive disease, but this selection could not explain the OS and RFS differences between the included mutants and wild-types.

This meta-analysis indicates that *KRAS* mutation status is a prognostic factor in patients undergoing resection of CLM irrespective of chemotherapy regimen and should be considered in the evaluation of patients undergoing liver resection for CLM. In practice, the use of *KRAS* mutation status alone cannot be recommended as grounds for excluding patients from surgery, but the finding of wild-type *KRAS* may encourage the use of more aggressive treatment in patients with borderline resectable disease. *KRAS* mutation status is clearly useful, together with other clinicopathological predictors, both in the preoperative assessment of patients with CLM and at follow-up to assess the risk of recurrence and death.

Acknowledgements

The authors particularly thank S. Deming (Department of Scientific Publications, MD Anderson Cancer Center) for copyediting the manuscript, and R. J. Haynes (Department of Surgical Oncology, MD Anderson Cancer Center) for editing the manuscript.

This work was supported in part by the National Institutes of Health by means of a Cancer Center Support Grant (Ca016672). K.W.B. is supported by Oslo University Hospital, Norway, and by a grant from the Unger-Vetlesen Medical Fund for 2014.

Disclosure: The authors declare no conflict of interest.

References

1 Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C *et al*. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. *J Clin Oncol* 2011; **29**: 1083–1090.

2 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 1999; **230**: 309–318.

3 Iwatsuki S, Dvorchik I, Madariaga JR, Marsh JW, Dodson F, Bonham AC *et al*. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. *J Am Coll Surg* 1999; **189**: 291–299.

4 Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. *Ann Surg* 2008; **247**: 125–135.

5 Nathan H, de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G *et al*. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. *J Am Coll Surg* 2010; **210**: 755–764, 764–766.

6 Reissfelder C, Rahbari NN, Koch M, Ulrich A, Pfeilschifter I, Waltert A *et al*. Validation of prognostic scoring systems for patients undergoing resection of colorectal cancer liver metastases. *Ann Surg Oncol* 2009; **16**: 3279–3288.

7 Zakaria S, Donohue JH, Que FG, Farnell MB, Schleck CD, Ilstrup DM *et al*. Hepatic resection for colorectal metastases: value for risk scoring systems? *Ann Surg* 2007; **246**: 183–191.

8 Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ *et al*. Wild-type *KRAS* is required for panitumumab efficacy in patients with metastatic colorectal cancer. *J Clin Oncol* 2008; **26**: 1626–1634.

9 Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M *et al*. Panitumumab–FOLFOX4 treatment and *RAS* mutations in colorectal cancer. *N Engl J Med* 2013; **369**: 1023–1034.

10 Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A *et al*. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; **360**: 1408–1417.

11 Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF *et al*. *KRAS* mutation status is predictive of response to cetuximab therapy in colorectal cancer. *Cancer Res* 2006; **66**: 3992–3995.

12 Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz LAJr, Donehower RC *et al*. Incidence and prognostic impact of *KRAS* and *BRAF* mutation in patients undergoing liver surgery for colorectal metastases. *Cancer* 2013; **119**: 4137–4144.

13 Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B *et al*. *KRAS* status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. *Br J Surg* 2012; **99**: 1575–1582.

14 Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A *et al*. *RAS* mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Ann Surg* 2013; **258**: 619–626.

15 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010; **8**: 336–341.

16 Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS *et al*. *KRAS* mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. *Ann Surg Oncol* 2010; **17**: 572–578.

17 Russo A, Migliavacca M, Bazan V, Maturi N, Morello V, Dardanoni G *et al*. Prognostic significance of proliferative activity, DNA-ploidy, *p53* and Ki-*ras* point mutations in colorectal liver metastases. *Cell Prolif* 1998; **31**: 139–153.

18 Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C *et al*. *KRAS* mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. *PLoS One* 2009; **4**: e8199.

19 Petrowsky H, Sturm I, Graubitz O, Kooby DA, Staib-Sebler E, Gog C *et al*. Relevance of Ki-67 antigen expression and K-*ras* mutation in colorectal liver metastases. *Eur J Surg Oncol* 2001; **27**: 80–87.

20 Huang CJ, Teng HW, Chien CC, Lin JK, Yang SH. Prognostic significance of C-reactive protein polymorphism and *KRAS/BRAF* in synchronous liver metastasis from colorectal cancer. *PLoS One* 2013; **8**: e65117.
21 Isella C, Mellano A, Galimi F, Petti C, Capussotti L, De Simone M *et al*. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. *Ann Surg* 2013; **257**: 1089–1095.
22 Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK *et al*. *BRAF* mutation is a prognostic biomarker for colorectal liver metastasectomy. *J Surg Oncol* 2012; **106**: 123–129.
23 Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S *et al*. Poor prognosis of *KRAS* or *BRAF* mutant colorectal liver metastasis without microsatellite instability. *J Hepatobiliary Pancreat Sci* 2013; **20**: 223–233.
24 Kemeny NE, Chou JF, Capanu M, Gewirtz AN, Cercek A, Kingham TP *et al*. *KRAS* mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. *Cancer* 2014; **120**: 3965–3971.
25 Shoji H, Yamada Y, Taniguchi H, Nagashima K, Okita N, Takashima A *et al*. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. *Cancer Sci* 2014; **105**: 1002–1007.
26 Kastrinakis WV, Ramchurren N, Maggard M, Steele G Jr, Summerhayes IC. K-*ras* status does not predict successful hepatic resection of colorectal cancer metastasis. *Arch Surg* 1995; **130**: 9–14.
27 Pollock CB, Shirasawa S, Sasazuki T, Kolch W, Dhillon AS. Oncogenic K-*RAS* is required to maintain changes in cytoskeletal organization, adhesion, and motility in colon cancer cells. *Cancer Res* 2005; **65**: 1244–1250.
28 Schramm K, Krause K, Bittroff-Leben A, Goldin-Lang P, Thiel E, Kreuser ED. Activated K-*ras* is involved in regulation of integrin expression in human colon carcinoma cells. *Int J Cancer* 2000; **87**: 155–164.
29 Serova M, Astorgues-Xerri L, Bieche I, Albert S, Vidaud M, Benhadji KA *et al*. Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells. *Mol Cancer Ther* 2010; **9**: 1308–1317.
30 Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW, Coffey RJ. Oncogenic *KRAS* provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. *J Cell Physiol* 2007; **210**: 740–749.
31 Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S *et al*. *BRAF* and *RAS* oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. *Mol Cancer* 2011; **10**: 118.
32 Vaughn CP, Zobell SD, Furtado LV, Baker CL, Samowitz WS. Frequency of *KRAS*, *BRAF*, and *NRAS* mutations in colorectal cancer. *Genes Chromosomes Cancer* 2011; **50**: 307–312.
33 Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S. *KRAS* as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. *Med Oncol* 2013; **30**: 650.
34 De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G *et al*. Effects of *KRAS*, *BRAF*, *NRAS*, and *PIK3CA* mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010; **11**: 753–762.
35 Italiano A, Hostein I, Soubeyran I, Fabas T, Benchimol D, Evrard S *et al*. *KRAS* and *BRAF* mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. *Ann Surg Oncol* 2010; **17**: 1429–1434.
36 Knijn N, Mekenkamp LJ, Klomp M, Vink-Borger ME, Tol J, Teerenstra S *et al*. *KRAS* mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. *Br J Cancer* 2011; **104**: 1020–1026.
37 Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M *et al*. *KRAS* mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. *Clin Cancer Res* 2011; **17**: 1122–1130.
38 Oudejans JJ, Slebos RJ, Zoetmulder FA, Mooi WJ, Rodenhuis S. Differential activation of *ras* genes by point mutation in human colon cancer with metastases to either lung or liver. *Int J Cancer* 1991; **49**: 875–879.
39 Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J *et al*. Comparative genomic analysis of primary *versus* metastatic colorectal carcinomas. *J Clin Oncol* 2012; **30**: 2956–2962.
40 Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G *et al*. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. *Clin Cancer Res* 2013; **19**: 4104–4113.
41 Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of *KRAS*, *NRAS*, *BRAF*, *PIK3CA* and *PTEN* for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. *Acta Oncol* 2014; **53**: 852–864.
42 Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F *et al*. Clinical validation of the detection of *KRAS* and *BRAF* mutations from circulating tumor DNA. *Nat Med* 2014; **20**: 430–435.
43 Netzel BC, Grebe SK. Companion-diagnostic testing limited to *KRAS* codons 12 and 13 misses 17% of potentially relevant *RAS* mutations in colorectal cancer. *Clin Chim Acta* 2013; **425**: 1–2.
44 Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ *et al*. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. *Eur J Surg Oncol* 2008; **34**: 55–60.
45 Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC *et al*. Regulatory T cell infiltration predicts

outcome following resection of colorectal cancer liver metastases. *Ann Surg Oncol* 2013; **20**: 946–955.
46 Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D *et al*. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. *Ann Surg* 2007; **246**: 806–814.
47 Minagawa M, Yamamoto J, Kosuge T, Matsuyama Y, Miyagawa S, Makuuchi M. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. *Arch Surg* 2007; **142**: 269–276.
48 Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P *et al*. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. *Cancer* 1996; **77**: 1254–1262.
49 Kattan MW, Gonen M, Jarnagin WR, DeMatteo R, D'Angelica M, Weiser M *et al*. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. *Ann Surg* 2008; **247**: 282–287.
50 Chun YS, Vauthey JN, Boonsirikamchai P, Maru DM, Kopetz S, Palavecino M *et al*. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. *JAMA* 2009; **302**: 2338–2344.
51 Shindoh J, Loyer EM, Kopetz S, Boonsirikamchai P, Maru DM, Chun YS *et al.* Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. *J Clin Oncol* 2012; **30**: 4566–4572.
52 Blazer DG III, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ *et al*. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. *J Clin Oncol* 2008; **26**: 5344–5351.
53 Mise Y, Zimmitti G, Shindoh J, Kopetz S, Loyer EM, Andreou A *et al*. *RAS* mutations predict radiologic and pathologic response in patients treated with chemotherapy prior to resection of colorectal liver metastases. *Ann Surg Oncol* 2015; **22**: 834–842.
54 Kawamoto Y, Tsuchihara K, Yoshino T, Ogasawara N, Kojima M, Takahashi M *et al*. *KRAS* mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. *Br J Cancer* 2012; **107**: 340–344.
55 Søreide K, Sandvik OM, Søreide JA. *KRAS* mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection? *Cancer* 2014; **120**: 3862–3865.